莫西沙星治疗泌尿生殖系支原体感染的对比研究

目的观察莫西沙星治疗泌尿生殖系支原体感染的临床疗效、安全性并与司帕沙星、左氧氟沙星进行比较. 方法 129例支原体感染的患者随机分为3组:莫西沙星组口服莫西沙星400 mg,qd,疗程为14 d;司帕沙星组口服司帕沙星200 mg,qd,疗程为14 d;左氧氟沙星组口服左氧氟沙星200 mg,bid,疗程为14 d;采用法国生物梅里埃IST试剂盒对患者标本进行支原体培养,并观察临床疗效及不良反应. 结果 3组患者临床痊愈率和总有效率分别是74.4%、65.1%、53.5%和95.3%、90.7%、69.8%;病原体清除率分别为90.7%、88.4%、67.4%.莫西沙星组、司帕沙星组与左氧氟沙星组相比差异有显著性意义,未发生严重的不良反应. 结论莫西沙星是一种治疗泌尿生殖系支原体感染高效、安全、服用方便的抗菌药物.

Moxifloxacin in Treatment of Mycoplasma Infection in Urinary and Reproductive System:Randomized Controlled Study

OBJECTIVE To observe the clinical efficacy and safety of moxifloxacin in treatment of mycoplasma infection in urinary and reproductive system and to compare moxifloxacin with sparfloxacin or levofloxacin. METHODS A total of 129 cases with mycoplasma infection in urinary and reproductive system were randomly assigned to three groups: moxifloxacin group was treated with moxifloxacin 400 mg qd for 14 d;sparfloxacin group was treated with sparfloxacin 200 mg qd for 14 d and levofloxacin group was treated with levofloxacin 200 mg bid for 14 d. Mycoplasma cultures with the use of the France Bio-Merieux IST kit were conducted in 129 cases. RESULTS The cure rates and overall effective rates of three groups were 74.4%,65.1%,53.5% and 95.3%, 90.7%, 69.8%,respectively. The pathogen clearance rates were 90.7%,88.4%,67.4%,respectively. There were significant difference between moxifloxacin and levofloxacin groups or sparfloxacin and levofloxacin groups;No severe adverse reaction occurred in three groups. CONCLUSIONS Moxifloxacin is a very effective antibiotic in treating mycoplasma infection in urinary and reproductive system with a few adverse reaction and convenient administration.